Participation in "Pharmaceutical Visionary Conference 2025
Discussions for Co-creation by Expanding the Circle of Stakeholders

Shinsuke Amano (President, National Federation of Cancer Patients' Associations)

The provision of information on clinical trials is about to undergo a major change with the Diet deliberations on the revision of the Clinical Research Act confirming that the provision of information should proceed, and now is the time for patients, medical professionals, companies and government to collaborate as in this conference.

Ken Annaka (Director, Pharmaceutical Industry Promotion and Medical Information Planning Division, Medical Policy Bureau, Ministry of Health, Labour and Welfare)

The first step in patient participation begins with telling someone about your needs and concerns. I would like to convey to everyone that "patient participation" does not have to be difficult to understand so that many people can participate.

Koji Ohguro (President, Japan Council of Associations for Intractable Diseases and Disorders)

There are many issues related to medicine and pharmaceuticals, but I see possibilities for the future in the frank dialogue with you all. We will continue to make concrete efforts to resolve the issues. Thank you very much for your cooperation.

Keiichi Ohzono (Director, Center for Intractable Diseases, Iiseikai International General Hospital)

I felt that such meetings play an important role in promoting the development of drugs while respecting each other's position, including those involved (patients and their families), medical professionals, pharmaceutical companies, and regulatory authorities.

Akiko Kashiwagi (Representative, Hidamari Tanpopo, a family group for patients with organic acid and fatty acid metabolism disorders)

While I sensed progress in access to clinical trial information and PPI, issues such as disparities in drug discovery and clinical trial information among patients and the public as a whole were also presented. From the standpoint of a patient group, I felt that we must continue to learn so that we can deliver useful information in an easy-to-understand manner not only to fellow patients with the same disease, but also to the general public.

Naomi Sakurai (Vice President, National Federation of Cancer Patients' Associations)

With the advancement of digital technology, the flow of information will change drastically in the future. Clinical trial information will also become a push type that can be delivered individually if desired, and I was reminded of the need to communicate our "vision" of how our medical environment will change.

Daisaku Sato, Deputy Director-General (Pharmaceuticals), Minister's Secretariat, Ministry of Health, Labour and Welfare

There were many things that I could understand as a real feeling after talking to them directly. I feel that opportunities for face-to-face dialogue are very important, not just imagining. It makes me feel that we should not think of reasons why we cannot do something, but rather think together about what we can do.

Kenichi Nakamura, Director, Division of International Development, National Cancer Center Hospital

It was a very meaningful time for me to have honest discussions with various stakeholders. I believe that we all share the same desire to create better pharmaceutical products, and I hope that we can co-create in various situations as colleagues aiming for the same goal.

Ms. Yukiko Nishimura (President, ASrid, a non-profit organization) (Moderator)

I felt a cycle of "dialogue" that enables us to understand the thoughts of those who are in different positions, and "continuing" the discussion fosters further development of the discussion. I hope that we can continue to have frank dialogues in the future, in order to lead to beneficial actions.

Yasuhiro Fujiwara (President, Pharmaceuticals and Medical Devices Agency (PMDA), Japan)

PMDA will continue to work with you all to promote patient and citizen participation for the realization of a world in which everyone can live healthy lives.

Asuka Miyabashira (Chairman, Japan Pharmaceutical Manufacturers Association)

We will continue to enhance our ability to communicate and co-create with you toward a society where PPI is a matter of course.